Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $52 price target.
June 25, 2024 | 9:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences and maintains a $52 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $52 price target by a reputable analyst suggests positive sentiment and confidence in Harmony Biosciences' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100